Multivalent linkers: A growing trend in antibody-drug conjugate development.
1/5 보강
Over the last 25 years, antibody-drug conjugates (ADCs) have evolved from a novelty to a well-established and clinically validated tool for cancer treatment.
APA
Gulyak EL, Korshun VA, Sapozhnikova KA (2026). Multivalent linkers: A growing trend in antibody-drug conjugate development.. Biotechnology advances, 89, 108841. https://doi.org/10.1016/j.biotechadv.2026.108841
MLA
Gulyak EL, et al.. "Multivalent linkers: A growing trend in antibody-drug conjugate development.." Biotechnology advances, vol. 89, 2026, pp. 108841.
PMID
41687936 ↗
Abstract 한글 요약
Over the last 25 years, antibody-drug conjugates (ADCs) have evolved from a novelty to a well-established and clinically validated tool for cancer treatment. Most ADCs are prepared by conjugating one payload per site via linear linkers. However, when conjugation is performed at a single position or a higher drug-to-antibody ratio (DAR) is desired, it becomes necessary to conjugate multiple drug moieties per site. This requires the use of multivalent linkers, which can be either low-molecular-weight branched structures or polymers. Several ADCs based on these linkers have reached clinical trials, and branched linkers are now being actively explored for preparing highly promising dual-payload conjugates. In this review, we comprehensively examine various multivalent linker architectures and explore the interplay between linker-payload design, conjugation strategies, and ADC properties and activity. We also evaluate the unique challenges associated with multivalent ADC linkers, such as increased local hydrophobicity and hindered payload release, as well as strategies for overcoming these hurdles. Further, we provide a future outlook for multivalent linker technologies, considering current trends in the rapidly evolving field of ADC development.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.